Bayer Schering Pharma Remains Optimistic About Growth In Asia Pacific Region, Won’t Join Acquisition Bandwagon
This article was originally published in PharmAsia News
Executive Summary
Bayer Schering Pharma has been enjoying double-digit growth in the Asia Pacific region for the past three years, and is confident in maintaining this momentum over the next few years, said Chris Lee, the company's Asia Pacific regional head. Bayer will expand its China workforce from the current 3,000 people to more than 4,000 people in the next two years. Lee said that the acquisition planned by Merck of Schering-Plough and by Pfizer of Wyeth will not pose a substantial threat to Bayer. He stressed that Bayer will not resort to an acquisition strategy as a counter-measure, and will instead rely on its strong R&D.(Click here for more - Chinese Language)
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.